Study: Majority of hospitals do not engage in HIE

Only one-third of hospitals in the U.S. engage in health information exchange (HIE) with unaffiliated providers, according to a study published in the Journal of Delivery Science and Innovation.

The study, conducted by researchers at Harvard University and the University of Michigan, utilized data from the 2010 and 2012 American Hospital Association surveys to measure HIE participation among hospitals and within states. They also analyzed whether hospitals are looking into joining an HIE.

The researchers found significant variation in state-level participation. Some states, like Rhode Island, Delaware and Vermont achieved more than 70 percent participation while others had minimal participation. While several of the states with high participation rates were small (i.e., few hospitals), some large states like New York and Indiana had among the highest rates. However, states with very low rates included both large states like Minnesota and very small states such as Alaska, North Dakota, New Hampshire and Wyoming.

Meanwhile, non-profit hospitals were more likely than for-profit hospitals to engage in HIE, and hospitals with a larger share of the market more often linked to exchanges, according to the study.

“Stronger policies and incentives may be needed to convince organizations to share their data electronically. Pursuing these is critical to ensuring that the highly anticipated quality and efficiency gains from our large national investment in health IT are realized," wrote Julia Adler-Milstein, PhD, lead author and assistant professor within the University of Michigan’s School of Public Health et al.

Read the full study here.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.